NOTES TO THE CONSOLIDATED FINANCIAL
STATEMENTS
(UNAUDITED)
NOTE 1 - THE COMPANY
Windstar, Inc. was incorporated in the
state of Nevada on September 6, 2007. On July 19, 2010, the Company amended its Articles of Incorporation to change the name of
the Company to Regenicin, Inc. (“Regenicin”). In September 2013, Regenicin formed a new wholly-owned subsidiary for
the sole purpose of conducting research in the State of Georgia (together, the “Company”). The subsidiary has no activity
since its formation due to the lack of funding.
The Company’s original business
was the development of a purification device. Such business was assigned to the Company’s former management in
July 2010.
The Company adopted a new business
plan and intended to develop and commercialize a potentially lifesaving technology by the introduction of tissue-engineered skin
substitutes to restore the qualities of healthy human skin for use in the treatment of burns, chronic wounds and a variety of
plastic surgery procedures.
The Company entered into a Know-How License
and Stock Purchase Agreement (the “Know-How SPA”) with Lonza Walkersville, Inc. (“Lonza Walkersville”)
on July 21, 2010. Pursuant to the terms of the Know-How SPA, the Company paid Lonza Walkersville $3,000,000 and, in exchange,
the Company was to receive an exclusive license to use certain proprietary know-how and information necessary to develop and seek
approval by the U.S. Food and Drug Administration (“FDA”) for the commercial sale of technology held by the Cutanogen
Corporation (“Cutanogen”), a subsidiary of Lonza Walkersville. Additionally, pursuant to the terms of the Know-How
SPA, the Company was entitled to receive certain related assistance and support from Lonza Walkersville upon payment of the $3,000,000.
Under the Know-How SPA, once FDA approval was secured for the commercial sale of the technology, the Company would be entitled
to acquire Cutanogen, Lonza Walkersville’s subsidiary, for $2,000,000 in cash.
After prolonged attempts to negotiate
disputes with Lonza Walkersville failed, on September 30, 2013, the Company filed a lawsuit against Lonza Walkersville, Lonza
Group Ltd. and Lonza America, Inc. (“Lonza America”) in Fulton County Superior Court in the State of Georgia.
On November 7, 2014, the Company entered
into an Asset Sale Agreement (the “Sale Agreement”) with Amarantus Bioscience Holdings, Inc., (“Amarantus”).
Under the Sale Agreement, the Company agreed to sell to Amarantus all of its rights and claims in the litigation currently pending
in the United States District Court for the District of New Jersey against Lonza Walkersville and Lonza America, Inc. (the “Lonza
Litigation”). This includes all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology.
In addition, the Company agreed to sell the PermaDerm® trademark and related intellectual property rights associated with
it. The purchase price paid by Amarantus was: (i) $3,600,000 in cash, and (ii) shares of common stock in Amarantus having a value
of $3,000,000 at the sale date. See Note 4 for a further discussion.
The Company is using the net proceeds of the transaction to
fund development of cultured cell technology and to pursue approval of the products through the FDA. The Company has been developing
its own unique cultured skin substitute since receiving Lonza’s termination notice.
NOTE 2 - BASIS OF PRESENTATION
Interim Financial Statements:
The accompanying unaudited consolidated
financial statements have been prepared in accordance with U.S. generally accepted accounting principles for interim financial
information and with Rule 8-03 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures
required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments
(consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for
the six months ended March 31, 2016 are not necessarily indicative of the results that may be expected for the year ending September
30, 2016. These unaudited consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and footnotes thereto included in the Company's Annual Report on Form 10-K for the year ended September 30, 2015, as
filed with the Securities and Exchange Commission.
Going Concern:
The Company's consolidated financial
statements have been prepared assuming that the Company will continue as a going concern which contemplates the realization of
assets and satisfaction of liabilities in the normal course of business. The Company has incurred cumulative losses and has an
accumulated deficit of approximately $11.4 million from inception, expects to incur further losses in the development of its business
and has been dependent on funding operations through the issuance of convertible debt and private sale of equity securities. These
conditions raise substantial doubt about the Company's ability to continue as a going concern. The Company is using the proceeds
from the Asset Sale to fund operations. Once the funds are exhausted, management plans to finance operations through the private
or public placement of debt and/or equity securities. However, no assurance can be given at this time as to whether the Company
will be able to obtain such financing. The consolidated financial statements do not include any adjustment relating to the recoverability
and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the
Company be unable to continue as a going concern.
Financial Instruments and Fair Value
Measurement:
The Company measures fair value of its financial assets on
a three-tier value hierarchy, which prioritizes the inputs, used in the valuation methodologies in measuring fair value:
• Level 1 - Observable inputs that reflect quoted
prices (unadjusted) for identical assets or liabilities in active markets.
• Level 2 - Observable inputs other than Level 1 prices,
such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities
in markets that are not active; inputs other than quoted prices that are observable or inputs that can be corroborated by observable
market data for substantially the full term of the assets or liabilities.
• Level 3 - Unobservable inputs which are supported
by little or no market activity.
The fair value hierarchy also requires an entity to maximize
the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.
The carrying value of cash, prepaid expenses and other current
assets, accounts payable, accrued expenses and all loans and notes payable in the Company’s consolidated balance sheets
approximated their values as of and March 31, 2016 and September 30, 2015 due to their short-term nature.
Common stock of Amarantus represents equity investments in
common stock that the Company classifies as available for sale. Such investments are carried at fair value in the accompanying
consolidated balance sheets. Fair value is determined under the guidelines of GAAP which defines fair value, establishes a framework
for measuring fair value and expands disclosures about fair value measurements. Realized gains and losses, determined using the
first-in, first-out (FIFO) method, are included in net income. Unrealized gains and losses considered to be temporary are reported
as other comprehensive income (loss) and are included in stockholders equity. Other than temporary declines in the fair value
of investment is included in other income (expense) on the statement of operations.
The common stock of Amarantus is valued at the closing price
reported on the active market on which the security is traded. This valuation methodology is considered to be using Level 1 inputs.
The total value of Amarantus common stock at March 31, 2016 is $13,650. The unrealized loss for the six months ended March 31,
2016 and 2015 was $286,350 and $1,500,000, net of income taxes, respectively, and was reported as a component of comprehensive
income (loss). The unrealized loss for the three months ended March 31, 2016 and 2015 was $145,100 and $966,000 net of income
taxes, respectively, and was reported as a component of comprehensive income (loss). During the fiscal year ended September 30,
2015, the Company recognized an other than temporary loss on the stock in the amount of $2.7 million which was recognized in the
statement of operations for that fiscal year.
Recent Pronouncements:
Management does not believe that any
of the recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying
consolidated financial statements.
Reclassifications:
Certain amounts have been
reclassified in the prior year financial statements presented herein, to conform to the current year presentation.
NOTE 3 - INCOME (LOSS) PER SHARE
Basic income (loss) per share is computed
by dividing the net income (loss) by the weighted average number of common shares outstanding during the period. Diluted loss
per share gives effect to dilutive convertible securities, options, warrants and other potential common stock outstanding during
the period; only in periods in which such effect is dilutive. The following table summarizes the components of the income (loss)
per common share calculation:
|
Six
Months Ended
March 31,
|
|
Three
Months Ended
March
31,
|
|
2016
|
|
2015
|
|
2016
|
|
2015
|
Income
(Loss) Per Common Share - Basic:
|
|
|
|
|
|
|
|
Net
income (loss) available to common stockholders
|
$
|
(693,199
|
)
|
|
$
|
3,672,689
|
|
|
$
|
(311,179
|
)
|
|
$
|
1,277,889
|
|
Weighted-average
common shares outstanding
|
|
153,483,050
|
|
|
|
153,041,442
|
|
|
|
153,483,050
|
|
|
|
153,457,176
|
|
Basic
income (loss) per share
|
$
|
(0.00
|
)
|
|
$
|
0.02
|
|
|
$
|
(0.00
|
)
|
|
$
|
0.01
|
|
Income
(Loss) Per Common Share - Diluted:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net
income (loss) available to common stockholders
|
$
|
(693,199
|
)
|
|
$
|
3,672,689
|
|
|
$
|
(311,179
|
)
|
|
$
|
1,277,889
|
|
Weighted-average
common shares outstanding
|
|
153,483,050
|
|
|
|
153,041,442
|
|
|
|
153,483,050
|
|
|
|
153,457,176
|
|
Convertible
preferred stock
|
|
|
|
|
|
8,850,000
|
|
|
|
0
|
|
|
|
8,850,000
|
|
Weighted-average
common shares outstanding and common share equivalents
|
|
153,483,050
|
|
|
|
161,891,442
|
|
|
|
153,483,050
|
|
|
|
162,307,176
|
|
Diluted
income (loss) per share
|
$
|
(0.00
|
)
|
|
$
|
0.02
|
|
|
$
|
(0.00
|
)
|
|
$
|
0.01
|
|
The following securities have been
excluded from the dilution per share calculation for the six months ended March 31, 2016, as
their effect would be anti-dilutive:
Options
|
|
13,542,688
|
|
Warrants
|
|
722,500
|
|
Convertible preferred stock
|
|
8,850,000
|
|
The following securities have been excluded
from the diluted per share calculation for the six months ended March 31, 2015 because the exercise price was greater than the
average market price of the common shares:
|
Options
|
|
|
15,542,688
|
|
|
Warrants
|
|
|
3,061,667
|
|
NOTE 4 - SALE OF ASSET
On November 7, 2014, the Company entered
into a Sale Agreement with Amarantus, Clark Corporate Law Group LLP ("CCLG") and Gordon & Rees, LLP (“Gordon
& Rees”). Under the Sale Agreement, the Company had agreed to sell to Amarantus all of its rights and claims in the
Lonza Litigation. These include all of the Cutanogen intellectual property rights and any Lonza manufacturing know-how technology.
In addition, the Company had agreed to sell its PermaDerm® trademark and related intellectual property rights associated with
it. The purchase price to be paid by Amarantus was: i) $3,500,000 in cash, and (ii) shares of common stock in Amarantus having
a value of $3,000,000. A portion of the cash purchase price was allocated to repay debt. On January 30, 2015, the agreement was
amended whereby the cash portion of the purchase price was increased by $100,000 to $3,600,000 and the final payment was extended
to February 20, 2015. Since Amarantus did not adhere to the original and amended agreements, the Company did not record the final
installment of $2.5 million until it was received on February 24, 2015.
The payments to CCLG, satisfied in full
the obligations owed to CCLG under its secured promissory note. The $3,000,000 in Amarantus common stock was satisfied by the
issuance of 37,500,000 shares of Amarantus common stock from Amarantus to the Company. In addition to the sale price, Amarantus
paid Gordon & Rees $450,000 upon entering the agreement. The payment to Gordon & Rees was to satisfy in full all contingent
litigation fees and costs owed to Gordon & Rees in connection with the Lonza Litigation.
During the six months ended March 31,
2015, the Company recorded a gain on the sale of assets of $6,604,431. In addition, as a result of the Sale Agreement, the Company
determined that it is no longer liable for accounts payable to Lonza in the amount of $973,374. The liability was reversed and
included in operating expenses as an item of income during the six months ended March 31, 2015.
The Company also granted to Amarantus
an exclusive five (5) year option to license any engineered skin designed for the treatment of patients designated as severely
burned by the FDA developed by the Company. Amarantus can exercise this option at a cost of $10,000,000 plus a royalty of 5% on
gross revenues in excess of $150 million.
NOTE 5 - INTANGIBLE ASSETS
As discussed in Note 1, the Company paid
$3,000,000 to Lonza in 2010 to purchase an exclusive know-how license and assistance in gaining FDA approval. The $3,000,000 payment
was recorded as an intangible asset. Due to ongoing disputes and pending any settlement of the lawsuit, the Company subsequently
determined that the value of the intangible asset and related intellectual property had been fully impaired. As a result, the
balance of the intangible asset was $-0- at September 30, 2014.
In August 2010, the Company paid $7,500
and obtained the rights to the trademarks PermaDerm® and TempaDerm® from KJR-10 Corp.
As discussed above in Note 4, the Company
sold its intangible assets on November 7, 2014.
NOTE 6 - LOANS PAYABLE
Loan Payable:
In February 2011, an investor advanced
$10,000. The loan does not bear interest and is due on demand. At both March 31, 2016 and September 30, 2015, the loan payable
totaled $10,000.
Loans Payable - Related Parties:
During the year ended September 30, 2015,
the Company recorded expenses that were paid directly by Randall McCoy, the Company’s Chief Executive Officer in prior years
and were submitted for reimbursement in the amount of $95,000. During the six months ended March 31, 2016 the Company repaid $15,151
of this loan. At March 31, 2016 and September 30, 2015, the outstanding balance was $79,849 and $95,000, respectively.
During the quarter ended
December 31, 2015, $15,500 of Company expenses were paid directly by John Weber, the Company’s Chief Financial Officer and
were submitted for reimbursement. During the quarter ended March 31, 2016 this amount was repaid to the Company.
NOTE 7 - BRIDGE FINANCING
On December 21, 2011, the Company issued
a $150,000 promissory note to an individual. The note bore interest so that the Company would repay $175,000 on the maturity date
of June 21, 2012, which correlated to an effective rate of 31.23%. Additional interest of 10% was charged on any late payments.
The note was not paid at the maturity date and the Company is incurring additional interest described above. At both March 31,
2016 and September 30, 2015, the note balance was $175,000.
NOTE 8 - INCOME TAXES
The Company did not incur current tax
expense for the three and six months ended March 31, 2016. The provision for income taxes of $863,300 and $2,829,000 for the three
and six months ended March 31, 2015, respectively represents deferred taxes.
At March 31, 2016, the Company had available
approximately $4.0 million of net operating loss carry forwards which expire in the years 2029 through 2035. However, the
use of the net operating loss carryforwards generated prior to September 30, 2011 totaling $0.7 million is limited under Section
382 of the Internal Revenue Code. Section 382 of the Internal Revenue Code of 1986, as amended (the Code), imposes an annual limitation
on the amount of taxable income that may be offset by a corporation’s NOLs if the corporation experiences an “ownership
change” as defined in Section 382 of the Code.
Significant components of the Company’s
deferred tax assets at March 31, 2016 and September 30, 2015 are as follows:
|
March
31, 2016
|
|
September
30, 2015
|
Net operating loss carry forwards
|
$
|
1,587,390
|
|
|
$
|
2,574,628
|
|
Unrealized loss
|
|
1,194,540
|
|
|
|
1,080,000
|
|
Stock based compensation
|
|
40,105
|
|
|
|
227,201
|
|
Accrued expenses
|
|
412,774
|
|
|
|
355,265
|
|
Total deferred tax assets
|
|
3,234,809
|
|
|
|
4,237,094
|
|
Valuation allowance
|
|
(3,234,809
|
)
|
|
|
(4,237,094
|
)
|
Net deferred tax assets
|
$
|
—
|
|
|
$
|
—
|
|
Due to the uncertainty of their realization,
a valuation allowance has been established for all of the income tax benefit for these deferred tax assets.
At both March 31, 2016 and September 30,
2015, the Company had no material unrecognized tax benefits and no adjustments to liabilities or operations were required. The
Company does not expect that its unrecognized tax benefits will materially increase within the next twelve months. The Company
recognizes interest and penalties related to uncertain tax positions in general and administrative expense. As of March 31, 2016
and 2015, the Company has not recorded any provisions for accrued interest and penalties related to uncertain tax positions.
The Company files its federal income
tax returns under a statute of limitations. The 2012 through 2015 tax years generally remain subject to examination by federal
tax authorities. The Company has not filed any of its state income tax returns since inception. Due to recurring losses, management
believes that once such returns are filed, the Company would incur state minimum tax liabilities that were not deemed material
to accrue.
NOTE 9 - STOCKHOLDERS’ DEFICIENCY
Preferred Stock:
Series A
Series A Preferred pays a dividend of
8% per annum on the stated value and have a liquidation preference equal to the stated value of the shares. Each share of Preferred
Stock has an initial stated value of $1 and are convertible into shares of the Company’s common stock at the rate of 10
for 1.
The dividends are cumulative commencing
on the issue date whether or not declared. Dividends amounted to $35,497 and $17,652 for the six and three months March 31, 2016,
respectively and $35,303 and $17,458, respectively for the corresponding periods in the prior year. At March 31, 2016 and September
30, 2015, dividends payable total $357,539 and $322,042, respectively.
At both March 31, 2016 and September
30, 2015, 885,000 shares of Series A Preferred were outstanding.
Series B
On January 23, 2012, the Company designated
a new class of preferred stock called Series B Convertible Preferred Stock (“Series B Preferred”). Four million shares
have been authorized with a liquidation preference of $2.00 per share. Each share of Series B Preferred is convertible into ten
shares of common stock. Holders of Series B Convertible Preferred Stock have a right to a dividend (pro-rata to each holder) based
on a percentage of the gross revenue earned by the Company in the United States, if any, and the number of outstanding shares
of Series B Convertible Preferred Stock, as follows: Year 1 - Total Dividend to all Series B holders = .03 x Gross Revenue in
the U.S. Year 2 - Total Dividend to all Series B holders = .02 x Gross Revenue in the U.S. Year 3 - Total Dividend to all Series
B holders = .01 x Gross Revenue in the U.S. At March 31, 2016, no shares of Series B Preferred are outstanding.
NOTE 10 - STOCK-BASED COMPENSATION
The Company accounts for equity instruments
issued in exchange for the receipt of goods or services from other than employees in accordance with FASB ASC 505, “
Equity
”. Costs are measured at the estimated fair value of the consideration received or the estimated fair value of
the equity instruments issued, whichever is more reliably measurable. The value of equity instruments issued for consideration
other than employee services is determined on the earlier of a performance commitment or completion of performance by the provider
of goods or services as defined by ASC 505.
On January 6, 2011, the
Company approved the issuance of 885,672 options to each of the four members of the board of directors at an exercise price
of $0.035, as amended, per share that were to expire on December 22, 2015. Effective as of the expiration date, the Company
extended the term of those options to December 31, 2018. All other contractual terms of the options remained the same. The
option exercise price was compared to the fair market value of the Company’s shares on the date when the extension was
authorized by the Company, resulting in the immediate recognition of $67,895 in compensation expense. There is no deferred
compensation expense associated with this transaction, since all extended options had previously been fully vested. The
extended options were valued utilizing the Black-Scholes option pricing model with the following assumptions: Exercise price
of $0.035, expected volatility of 208%, risk free rate of 1.31% and expected term of 3.03 years. Stock based compensation
amounted to $67,895 and $32,365 for the six months ended March 31, 2016 and 2015, respectively, and $0 and $32,365 for the
three months ended March 31, 2016 and 2015, respectively. Stock-based compensation is included in general and administrative
expenses.
NOTE 11 - RELATED
PARTY TRANSACTIONS
The Company’s principal executive
offices are located in Little Falls, New Jersey. The headquarters is located in the offices of McCoy Enterprises LLC, an entity
controlled by Mr. McCoy. The office is attached to his residence but has its own entrances, restroom and kitchen facilities.
The Company also maintains an office
at Carbon & Polymer Research Inc. ("CPR") in Pennington, New Jersey, which is the Company's materials and testing laboratory.
An employee of the Company is an owner of CPR.
No rent is charged for either premise.
On May 16, 2016, the Company entered
into an agreement with CPR in which CPR will supply the collagen scaffolds used in the Company's production of the skin tissue.
The contract contains a most favored customer clause guaranteeing the Company prices equal or lower than those charged to other
customers.
NOTE 12 - SUBSEQUENT EVENTS
Management has evaluated subsequent events
through the date of this filing.